Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.
Cortellini A, Cocciolone V, Irelli A, Pavese F, Sidoni T, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Bonfili P, Franzese P, Zugaro L, Verna L, Porzio G, Santini D, Cannita K, Ficorella C. Cortellini A, et al. Among authors: sidoni t. Oncol Lett. 2018 Dec;16(6):7195-7203. doi: 10.3892/ol.2018.9561. Epub 2018 Oct 10. Oncol Lett. 2018. PMID: 30546457 Free PMC article.
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience.
Parisi A, Palluzzi E, Cortellini A, Sidoni T, Cocciolone V, Lanfiuti Baldi P, Porzio G, Ficorella C, Cannita K. Parisi A, et al. Among authors: sidoni t. Clin Transl Oncol. 2020 Jan;22(1):158-162. doi: 10.1007/s12094-019-02122-x. Epub 2019 Apr 30. Clin Transl Oncol. 2020. PMID: 31041717 Clinical Trial.
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status.
Irelli A, Parisi A, D'Orazio C, Sidoni T, Rotondaro S, Patruno L, Pavese F, Bafile A, Resta V, Pizzorno L, Ciuffetelli V, Dal Mas A, Calvisi G, Di Sibio A, Marzullo A, Zelli V, Compagnoni C, Tessitore A, Alesse E, Ficorella C, Cortellini A, Cannita K. Irelli A, et al. Among authors: sidoni t. Cancers (Basel). 2022 Jun 18;14(12):3003. doi: 10.3390/cancers14123003. Cancers (Basel). 2022. PMID: 35740668 Free PMC article.
Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis.
Cocciolone V, Cannita K, Calandrella ML, Ricevuto E, Baldi PL, Sidoni T, Irelli A, Paradisi S, Pizzorno L, Resta V, Bafile A, Alesse E, Tessitore A, Ficorella C. Cocciolone V, et al. Among authors: sidoni t. Oncotarget. 2017 Jun 16;8(42):72031-72043. doi: 10.18632/oncotarget.18526. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069766 Free PMC article.
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.
Cortellini A, Bersanelli M, Buti S, Gambale E, Atzori F, Zoratto F, Parisi A, Brocco D, Pireddu A, Cannita K, Iacono D, Migliorino MR, Gamucci T, De Tursi M, Sidoni T, Tiseo M, Michiara M, Papa A, Angius G, Tomao S, Fargnoli MC, Natoli C, Ficorella C. Cortellini A, et al. Among authors: sidoni t. Immunotherapy. 2018 Jun;10(8):643-655. doi: 10.2217/imt-2017-0167. Epub 2018 Mar 22. Immunotherapy. 2018. PMID: 29562816
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Cocciolone V, Cannita K, Tessitore A, Mastroiaco V, Rinaldi L, Paradisi S, Irelli A, Baldi PL, Sidoni T, Ricevuto E, Dal Mas A, Calvisi G, Coletti G, Ciccozzi A, Pizzorno L, Resta V, Bafile A, Alesse E, Ficorella C. Cocciolone V, et al. Among authors: sidoni t. Oncotarget. 2018 Jun 8;9(44):27380-27396. doi: 10.18632/oncotarget.25270. eCollection 2018 Jun 8. Oncotarget. 2018. PMID: 29937992 Free PMC article.
16 results